492 related articles for article (PubMed ID: 15642702)
21. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S
Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366
[TBL] [Abstract][Full Text] [Related]
22. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Colomer R; Lupu R
J Natl Cancer Inst; 2005 Nov; 97(21):1611-5. PubMed ID: 16264182
[TBL] [Abstract][Full Text] [Related]
23. tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).
Menendez JA; Vazquez-Martin A; Garcia-Villalba R; Carrasco-Pancorbo A; Oliveras-Ferraros C; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2008 Dec; 8():377. PubMed ID: 19094209
[TBL] [Abstract][Full Text] [Related]
24. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
25. 3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.
Ahmad A; Ali S; Ahmed A; Ali AS; Raz A; Sakr WA; Rahman KM
PLoS One; 2013; 8(1):e54657. PubMed ID: 23372748
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interactions between tamoxifen and trastuzumab (Herceptin).
Argiris A; Wang CX; Whalen SG; DiGiovanna MP
Clin Cancer Res; 2004 Feb; 10(4):1409-20. PubMed ID: 14977844
[TBL] [Abstract][Full Text] [Related]
27. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
Cardoso F; Durbecq V; Laes JF; Badran B; Lagneaux L; Bex F; Desmedt C; Willard-Gallo K; Ross JS; Burny A; Piccart M; Sotiriou C
Mol Cancer Ther; 2006 Dec; 5(12):3042-51. PubMed ID: 17148762
[TBL] [Abstract][Full Text] [Related]
29. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
30. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
31. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
[TBL] [Abstract][Full Text] [Related]
32. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines.
Mayfield S; Vaughn JP; Kute TE
Breast Cancer Res Treat; 2001 Nov; 70(2):123-9. PubMed ID: 11768602
[TBL] [Abstract][Full Text] [Related]
33. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells.
McKenzie T; Liu Y; Fanale M; Swisher SG; Chada S; Hunt KK
Surgery; 2004 Aug; 136(2):437-42. PubMed ID: 15300212
[TBL] [Abstract][Full Text] [Related]
35. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
36. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
Menendez JA; Vellon L; Oza BP; Lupu R
J Cell Biochem; 2005 Apr; 94(5):857-63. PubMed ID: 15669079
[TBL] [Abstract][Full Text] [Related]
37. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.
Voutsas IF; Mahaira LG; Fotopoulou K; Kapranos N; Reclos JG; Gritzapis AD; Papamichail M; Perez SA; Baxevanis CN
Int J Radiat Biol; 2013 May; 89(5):319-25. PubMed ID: 23311575
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Sonoue H; Matsumoto T; Sasai K; Tsurumaru M
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):203-11. PubMed ID: 15629613
[TBL] [Abstract][Full Text] [Related]
39. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
40. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
